Title:
抗癌治療
Document Type and Number:
Japanese Patent JP2008517991
Kind Code:
A
Abstract:
A method of treating the human body for cancer comprises administering an effective therapeutic amount of a Pegylated Liposomal form of the anthracycline Doxorubicin ("PLD"), in combination with an effective therapeutic amount of ET-743
Inventors:
Jill, Erard
Sternas, Lars-Axel
Trifan, Ovid
Van de Verde, Hergi
Titelbaum, April
Sternas, Lars-Axel
Trifan, Ovid
Van de Verde, Hergi
Titelbaum, April
Application Number:
JP2007538524A
Publication Date:
May 29, 2008
Filing Date:
October 26, 2005
Export Citation:
Assignee:
PHARMA MAR S.A., SOCIEDAD UNIPERSONAL
ORTHO BIOTECH PRODUCTS L.P.
ORTHO BIOTECH PRODUCTS L.P.
International Classes:
A61K31/4995; A61K9/08; A61K9/127; A61K31/704; A61P35/00; A61P43/00; A61K9/19; A61K47/02; A61K47/10
Domestic Patent References:
| JPH05501264A | 1993-03-11 |
Foreign References:
| WO2002036135A2 | 2002-05-10 |
Other References:
JPN5007018494, ＬＡＶＥＲＤＩＥＲＥ ＣＡＲＯＬＩＮＥ, ＣＡＮＣＥＲ, 20030815, Ｖ９８ Ｎ４, Ｐ８３２−８４０, US, ＡＭＥＲＩＣＡＮ ＣＡＮＣＥＲ ＳＯＣＩＥＴＹ
JPN5007018495, ＴＡＫＡＨＡＳＨＩ Ｎ, ＣＬＩＮＩＣＡＬ ＣＡＮＣＥＲ ＲＥＳＥＡＲＣＨ, 200110, Ｖ７ Ｎ１０, Ｐ３２５１−３２５７, US, ＴＨＥ ＡＭＥＲＩＣＡＮ ＡＳＳＯＣＩＡＴＩＯＮ ＦＯＲ ＣＡＮＣＥＲ ＲＥＳＥＡＲＣＨ
JPN6008057710, Ｋａｔｉａ Ｓｃｏｔｌａｎｄｉ ｅｔ ａｌ．, "Ｅｆｆｅｃｔｉｖｅｎｅｓｓ ｏｆ Ｅｃｔｅｉｎａｓｃｉｄｉｎ−７４３ ａｇａｉｎｓｔ Ｄｒｕｇ−ｓｅｎｓｉｔｉｖｅ ａｎｄ −ｒｅｓｉｓｔａｎｔ Ｂｏｎｅ Ｔｕｍｏｒ Ｃｅｌｌｓ", Ｃｌｉｎｉｃａｌ Ｃａｎｃｅｒ Ｒｅｓｅａｒｃｈ, 20021201, Ｖｏｌ． ８， Ｎｏ． １２, ｐｐ． ３８９３−３９０３
JPN6008057712, Ｒ． Ｒｉｃｃａｒｄｉ ｅｔ ａｌ．, "Ｅｆｆｅｃｔｉｖｅ Ｃｏｍｂｉｎａｔｉｏｎｓ ｏｆ ＥＴ−７４３ ａｎｄ Ｄｏｘｏｒｕｂｉｃｉｎ ｆｏｒ Ｔｕｍｏｒ Ｇｒｏｗｔｈ Ｉｎｈｉｂｉｔｉｏｎｓ Ａｇａｉｎｓｔ Ｍｕｒｉｎｅ ａｎｄ Ｈｕｍ", Ｐｒｏｃｅｅｄｉｎｇｓ． Ａｎｎｕａｌ Ｍｅｅｔｉｎｇ ｏｆ ｔｈｅ Ａｍｅｒｉｃａｎ Ａｓｓｏｃｉａｔｉｏｎ ｆｏｒ Ｃａｎｃｅｒ Ｒｅｓｅａｒｃｈ, 200103, Ｖｏｌ． ４２, ｐ． ２１１， ＃１１３２
JPN6008057714, Ａｔｓｕｋｏ Ｋａｎｚａｋｉ ｅｔ ａｌ．, "Ｏｖｅｒｃｏｍｉｎｇ Ｍｕｌｔｉｄｒｕｇ Ｄｒｕｇ Ｒｅｓｉｓｔａｎｃｅ ｉｎ Ｐ−Ｇｌｙｃｏｐｒｏｔｅｉｎ／ＭＤＲ１−ｏｖｅｒｅｘｐｒｅｓｓｉｎｇ Ｃｅｌｌ Ｌｉｎｅｓ ｂｙ Ｅｃｔｅｉｎａｓｃｉｄ", Ｍｏｌｅｃｕｌａｒ Ｃａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ, 20021201, Ｖｏｌ． １， Ｎｏ． １４, ｐｐ． １３２７−１３３４
JPN6008057716, Ｂ． Ｕｚｉｅｌｙ ｅｔ ａｌ．, "Ｌｉｐｏｓｏｍａｌ ｄｏｘｏｒｕｂｉｃｉｎ： ａｎｔｉｔｕｍｏｒ ａｃｔｉｖｉｔｙ ａｎｄ ｕｎｉｑｕｅ ｔｏｘｉｃｉｔｉｅｓ ｄｕｒｉｎｇ ｔｗｏ ｃｏｍｐｌｅｍｅｎｔａｒｙ ｐｈａｓｅ Ｉ ｓｔｕ", Ｊｏｕｒｎａｌ ｏｆ Ｃｌｉｎｉｃａｌ Ｏｎｃｏｌｏｇｙ, 19950701, Ｖｏｌ． １３， Ｎｏ． ７, ｐｐ． １７７７−１７８５
JPN5007018493, ［ＯＮＬＩＮＥ］, 20041010, Ｐ１−１４
JPN7008008190, Ｔ． Ｌ． Ｍ． ｔｅｎ Ｈａｇｅｎ， ｅｔ ａｌ．, "Ｐｅｇｙｌａｔｅｄ ｌｉｐｏｓｏｍａｌ ｔｕｍｏｒ ｎｅｃｒｏｓｉｓ ｆａｃｔｏｒ−ａｌｐｈａ ｒｅｓｕｌｔｓ ｉｎ ｒｅｄｕｃｅｄ ｔｏｘｉｃｉｔｙ ａｎｄ ｓｙｎｅｒｇｉｓｔｉｃ ａｎｔｉｔｕｍｏ", Ｉｎｔｅｒｎａｔｉｏｎａｌ ｊｏｕｒｎａｌ ｏｆ ｃａｎｃｅｒ, 20020101, Ｖｏｌ． ９７， Ｎｏ． １, ｐｐ． １１５−２０
JPN7008008191, Ｏ． Ｌｙａｓｓ ｅｔ ａｌ．, "Ｐｈａｓｅ Ｉ ｓｔｕｄｙ ｏｆ ｄｏｘｉｌ−ｃｉｓｐｌａｔｉｎ ｃｏｍｂｉｎａｔｉｏｎ ｃｈｅｍｏｔｈｅｒａｐｙ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ａｄｖａｎｃｅｄ ｍａｌｉｇｎａｎｃｉｅｓ．", Ｃｌｉｎｉｃａｌ ｃａｎｃｅｒ ｒｅｓｅａｒｃｈ, 200110, Ｖｏｌ． ７， Ｎｏ． １０, ｐｐ． ３０４０−３０４６
JPN7008008192, Ｈ． Ｊ． Ｂｕｒｓｔｅｉｎ ｅｔ ａｌ．, "Ｐｈａｓｅ Ｉ ｓｔｕｄｙ ｏｆ Ｄｏｘｉｌ ａｎｄ ｖｉｎｏｒｅｌｂｉｎｅ ｉｎ ｍｅｔａｓｔａｔｉｃ ｂｒｅａｓｔ ｃａｎｃｅｒ．", Ａｎｎａｌｓ ｏｆ Ｏｎｃｏｌｏｇｙ, 199909, Ｖｏｌ． １０， Ｎｏ． ９, ｐｐ． １１１３−１１１６
JPN5007018495, ＴＡＫＡＨＡＳＨＩ Ｎ, ＣＬＩＮＩＣＡＬ ＣＡＮＣＥＲ ＲＥＳＥＡＲＣＨ, 200110, Ｖ７ Ｎ１０, Ｐ３２５１−３２５７, US, ＴＨＥ ＡＭＥＲＩＣＡＮ ＡＳＳＯＣＩＡＴＩＯＮ ＦＯＲ ＣＡＮＣＥＲ ＲＥＳＥＡＲＣＨ
JPN6008057710, Ｋａｔｉａ Ｓｃｏｔｌａｎｄｉ ｅｔ ａｌ．, "Ｅｆｆｅｃｔｉｖｅｎｅｓｓ ｏｆ Ｅｃｔｅｉｎａｓｃｉｄｉｎ−７４３ ａｇａｉｎｓｔ Ｄｒｕｇ−ｓｅｎｓｉｔｉｖｅ ａｎｄ −ｒｅｓｉｓｔａｎｔ Ｂｏｎｅ Ｔｕｍｏｒ Ｃｅｌｌｓ", Ｃｌｉｎｉｃａｌ Ｃａｎｃｅｒ Ｒｅｓｅａｒｃｈ, 20021201, Ｖｏｌ． ８， Ｎｏ． １２, ｐｐ． ３８９３−３９０３
JPN6008057712, Ｒ． Ｒｉｃｃａｒｄｉ ｅｔ ａｌ．, "Ｅｆｆｅｃｔｉｖｅ Ｃｏｍｂｉｎａｔｉｏｎｓ ｏｆ ＥＴ−７４３ ａｎｄ Ｄｏｘｏｒｕｂｉｃｉｎ ｆｏｒ Ｔｕｍｏｒ Ｇｒｏｗｔｈ Ｉｎｈｉｂｉｔｉｏｎｓ Ａｇａｉｎｓｔ Ｍｕｒｉｎｅ ａｎｄ Ｈｕｍ", Ｐｒｏｃｅｅｄｉｎｇｓ． Ａｎｎｕａｌ Ｍｅｅｔｉｎｇ ｏｆ ｔｈｅ Ａｍｅｒｉｃａｎ Ａｓｓｏｃｉａｔｉｏｎ ｆｏｒ Ｃａｎｃｅｒ Ｒｅｓｅａｒｃｈ, 200103, Ｖｏｌ． ４２, ｐ． ２１１， ＃１１３２
JPN6008057714, Ａｔｓｕｋｏ Ｋａｎｚａｋｉ ｅｔ ａｌ．, "Ｏｖｅｒｃｏｍｉｎｇ Ｍｕｌｔｉｄｒｕｇ Ｄｒｕｇ Ｒｅｓｉｓｔａｎｃｅ ｉｎ Ｐ−Ｇｌｙｃｏｐｒｏｔｅｉｎ／ＭＤＲ１−ｏｖｅｒｅｘｐｒｅｓｓｉｎｇ Ｃｅｌｌ Ｌｉｎｅｓ ｂｙ Ｅｃｔｅｉｎａｓｃｉｄ", Ｍｏｌｅｃｕｌａｒ Ｃａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ, 20021201, Ｖｏｌ． １， Ｎｏ． １４, ｐｐ． １３２７−１３３４
JPN6008057716, Ｂ． Ｕｚｉｅｌｙ ｅｔ ａｌ．, "Ｌｉｐｏｓｏｍａｌ ｄｏｘｏｒｕｂｉｃｉｎ： ａｎｔｉｔｕｍｏｒ ａｃｔｉｖｉｔｙ ａｎｄ ｕｎｉｑｕｅ ｔｏｘｉｃｉｔｉｅｓ ｄｕｒｉｎｇ ｔｗｏ ｃｏｍｐｌｅｍｅｎｔａｒｙ ｐｈａｓｅ Ｉ ｓｔｕ", Ｊｏｕｒｎａｌ ｏｆ Ｃｌｉｎｉｃａｌ Ｏｎｃｏｌｏｇｙ, 19950701, Ｖｏｌ． １３， Ｎｏ． ７, ｐｐ． １７７７−１７８５
JPN5007018493, ［ＯＮＬＩＮＥ］, 20041010, Ｐ１−１４
JPN7008008190, Ｔ． Ｌ． Ｍ． ｔｅｎ Ｈａｇｅｎ， ｅｔ ａｌ．, "Ｐｅｇｙｌａｔｅｄ ｌｉｐｏｓｏｍａｌ ｔｕｍｏｒ ｎｅｃｒｏｓｉｓ ｆａｃｔｏｒ−ａｌｐｈａ ｒｅｓｕｌｔｓ ｉｎ ｒｅｄｕｃｅｄ ｔｏｘｉｃｉｔｙ ａｎｄ ｓｙｎｅｒｇｉｓｔｉｃ ａｎｔｉｔｕｍｏ", Ｉｎｔｅｒｎａｔｉｏｎａｌ ｊｏｕｒｎａｌ ｏｆ ｃａｎｃｅｒ, 20020101, Ｖｏｌ． ９７， Ｎｏ． １, ｐｐ． １１５−２０
JPN7008008191, Ｏ． Ｌｙａｓｓ ｅｔ ａｌ．, "Ｐｈａｓｅ Ｉ ｓｔｕｄｙ ｏｆ ｄｏｘｉｌ−ｃｉｓｐｌａｔｉｎ ｃｏｍｂｉｎａｔｉｏｎ ｃｈｅｍｏｔｈｅｒａｐｙ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ａｄｖａｎｃｅｄ ｍａｌｉｇｎａｎｃｉｅｓ．", Ｃｌｉｎｉｃａｌ ｃａｎｃｅｒ ｒｅｓｅａｒｃｈ, 200110, Ｖｏｌ． ７， Ｎｏ． １０, ｐｐ． ３０４０−３０４６
JPN7008008192, Ｈ． Ｊ． Ｂｕｒｓｔｅｉｎ ｅｔ ａｌ．, "Ｐｈａｓｅ Ｉ ｓｔｕｄｙ ｏｆ Ｄｏｘｉｌ ａｎｄ ｖｉｎｏｒｅｌｂｉｎｅ ｉｎ ｍｅｔａｓｔａｔｉｃ ｂｒｅａｓｔ ｃａｎｃｅｒ．", Ａｎｎａｌｓ ｏｆ Ｏｎｃｏｌｏｇｙ, 199909, Ｖｏｌ． １０， Ｎｏ． ９, ｐｐ． １１１３−１１１６
Attorney, Agent or Firm:
Michiharu Soga
Hidetoshi Furukawa
Suzuki Kenchi
Kajinami order
Kazuhiro Oyaku
Hidetoshi Furukawa
Suzuki Kenchi
Kajinami order
Kazuhiro Oyaku